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ABSTRACT 
The widespread nature of diabetes affects all organ systems of an individual including the bone 
marrow. Long-term damage to the cellular and extracellular components of the bone marrow leads to 
a rapid decline in the bone marrow-hematopoietic stem/progenitor cells (HS/PCs) compartment. This 
review will highlight the importance of bone marrow microenvironment in maintaining bone marrow 
HS/PC populations and the contribution of these key populations in microvascular repair during the 
natural history of diabetes. The autonomic nervous system can initiate and propagate bone marrow 
dysfunction in diabetes. Systemic pharmacological strategies designed to protect the bone marrow-
HS/PC population from diabetes induced-oxidative stress and advanced glycation end product 
accumulation represent a new approach to target diabetic retinopathy progression. Protecting 
HS/PCs ensures their participation in vascular repair and reduces the risk of vasogdegeneration 
occurring in the retina.    
 
Key Words: Diabetic retinopathy, bone marrow microenvironment, hematopoietic stem cells. 
 
Disclosures 
The authors declare that they have no conflicts of interest including any financial, personal or other 
relationships with other people or organizations within three years of beginning the submitted work 
that could inappropriately influence, or be perceived to influence, this work. All authors have 
materially participated in the research and/or article preparation of this article. All authors have 
approved the final article. All animal experiments comply with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978). 
 
Support  
AB: (i) Ralph and Grace Showalter Trust Fund (ii) International Retinal Research Foundation. AB 
and MG: an unrestricted award from Research to Prevent Blindness (RPB) foundation to 
3 
 
Department of Ophthalmology, Indiana University. MG; NIH grants: R01EY0126001, 
R01EY007739, R01HL110170, R01DK090730. JB; NIH RO1EY016077. MG and JB; MEAS Grant 
MICL02163. 
 
  
4 
 
1. INTRODUCTION  
Based on an epidemiology study published in 2014, diabetes affects 382 million people 
worldwide [1]. Moreover, the prevalence of diabetes continues to increase globally: about 592 million 
people are estimated to be diagnosed with diabetes by 2035 [1]. Diabetic retinopathy (DR) is the most 
prevalent complication of diabetes and affects about 93 million individuals worldwide. DR accounts 
for 4.8% of the number of cases of blindness (37 million) worldwide [2-4]. The number of individuals 
with vision-threatening DR, such as severe non-proliferative DR (NPDR) and PDR, is estimated to 
rise to 191 million by 2030. The number of individuals with diabetic macular edema (DME) is expected 
to increase to 56.3 million by that same year [5, 6]. Importantly, the presence of DR indicates 
microcirculatory dysfunction in other organ systems [7]. Despite better control of the modifiable risk 
factors (glucose, blood pressure and lipids) and better screening programs, DR remains a global 
health issue. A weakness of current therapies for DR (laser photocoagulation, injection of 
corticosteroids or anti-VEGF antibodies, or vitreoretinal surgery) is that these approaches do not 
correct the underlying pathology and carry significant side effects.  
The pathogenesis of DR suggests that it is a progressive vasodegenerative condition 
associated first with the loss of contractile pericytes followed by a widespread death of endothelial 
cells. Loss of this cellular support system culminates in under perfused areas of ischemia, depriving 
retina of a vital nutrient supply which triggers the remaining endothelium to release “vessel building” 
cytokines and growth factors such as vascular endothelial growth factor (VEGF). In addition, the retina 
faces a unique challenge in diabetes due to the combination of high metabolic demand and minimal 
vascular supply. This limits the retina’s ability to adapt to the metabolic stress of diabetes. The retina 
can lose as much as 38% of resident endothelial cells within 20 months of experimental diabetes [8].  
DR typically progresses because hyperglycemia and dyslipidemia are not adequately 
controlled [9, 10]. While all microvascular beds are affected by diabetes, the ones resulting in the 
most profound impact on the diabetic individual are the kidney, retina, and large nerves.  The resultant 
nephropathy, retinopathy, and neuropathy share common etiologies and pathogenic mechanisms 
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including altered metabolic and functional/hemodynamic factors and disturbed interactions between 
environmental, hormonal and genetic factors [11]. 
In this review, we are focusing on understanding the contribution of the bone marrow in the 
pathogenesis of DR and we provide an argument that the bone marrow should be considered a new 
target tissue for treatment of DR.   
2. BONE MARROW AND HEMATOPOIETIC STEM/PROGENITOR CELLS (HS/PCs)  
The bone marrow provides the primary conducive environment to harbor HS/PCs in adults 
and children. The bone marrow can selectively give rise to a variety of cell types, including lymphoid 
and myeloid cells, platelets, and red blood cells [12, 13]. About a million mature blood cells are 
produced per second in the normal adult human bone marrow. While the majority of HSCs are in G0 
phase, it is interesting to note that under physiologic conditions, there exists a perfect balance 
between responding to the enormous demand for hematopoietic cells and the preservation of an 
adequate pool of HSCs. This balance between regulated self-renewal, expansion, and differentiation 
is of critical importance as too little self-renewal can jeopardize the ability of the bone marrow to 
sustain hematopoiesis throughout the lifetime of the individual while excessive differentiation can 
result in aberrant phenotypes such as leukemogenesis [14].  Normally, HSCs give rise to 10% myeloid 
and 90% lymphoid donor type cells; however, this balance may shift towards more myeloid and less 
lymphoid cell types with a disease state such as diabetes or in aging, creating myeoloidosis [15].  
Diabetes leads to changes in cellular metabolism that result in overproduction of reactive 
oxygen species, genetic instability, and disruption of homeostatic pathways. These metabolic 
changes, not unexpectedly, adversely affect the bone marrow and lead to the myeoloidosis [16]. The 
bone marrow provides specialized niches for specific stem cell types [13]. The spindle-shaped N-
cadherin expressing osteoblast cells (SNO) lining the endosteal bone surface act as the endosteal 
niche for the HSCs while the bone marrow sinusoids together with HSCs constitute the vascular niche 
in the bone marrow (Figure 1). The HSCs near the endosteum are the longest-lived cells possessing 
unlimited self-renewal potential and are called long-term repopulating HSCs (LTR-HSCs). The well-
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orchestrated dynamics of the processes of self-renewal and release governs the supply of HSCs 
present in the circulation (15). LTR-HSCs respond to stimuli or injury and travel to the sinusoid; at 
this point, they lose their unlimited self-renewal capability and become committed short-term 
repopulating HSCs (STR-HSCs). Typically, 60% of STR-HSCs are found near sinusoidal niche, while 
only 20% of HSCs (i.e. LTR-HSCs) are at the endosteal surface. These two bone marrow stem cell 
niches have different oxygen levels further distinguishing their specialization. 
Figure 1: Localization of c-Kit+ cells in mouse bone marrow. Upper panel: immunofluorescence staining 
of N-cadherin (red) and c-Kit (green) in demineralized mouse femurs. Some c-Kit+ cells (white arrow) 
localized to endosteal niche (blue arrow) are defined as long-term repopulating (LTR)-hematopoietic stem 
cells (HSCs); Lower panel: mouse femurs stained for VE-cadherin (red) and c-Kit (green). c-Kit+ cells (white 
arrow) located at vascular niche are defined as short-term repopulating (STR)-HSCs. Representative 
images showing a reduced number of LTR-HSCs and increased STR-HSCs/LTR-HSCs in the STZ-induced 
diabetic bone marrow. ATM-/- intensified diabetes-mediated defects of LTR- and STR-HSCs imbalance in 
the bone marrow. Abbreviations: WT, wild type; STZ, streptozotocin; ATM, ataxia telangiectasia mutated. 
 
2.1 KEY MOLECULAR TARGETS AFFECTING BONE MARROW FUNCTION    
We reported that ataxia telangiectasia mutated (ATM) is critical for maintaining long-term 
populating HSCs in the bone marrow [17]. ATM helps correct DNA damage by recruiting DNA repair 
proteins to sites of DNA damage. The ATM is necessary for the survival of LTR-HSCs and the loss 
of ATM results in an increase in more committed STR-HSCs. This imbalance may eventually 
WT STZ ATM-/- STZ
N-cadherin
c-Kit
VE-cadherin
c-Kit
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contribute to the development of diabetic retinopathy. Forkhead box-O (FoxO) also plays a critical 
role in maintaining HSC population. Conditional deletion of FoxO isoforms FoxO1, FoxO3, and FoxO4 
from bone marrow induces HSC imbalance (less LTR-HSC and more STR-HSC) results in an 
increase in oxidative stress [18-20], whereas overexpression of FoxO decreases oxidative stress and 
apoptosis [21]. The functional interaction between FoxO3 and ATM halts DNA damage due to 
activation of DNA damage-inducible gene 45 (Gadd45). 
In addition to hyperglycemia-induced bone marrow damage, we also reported that dyslipidemia 
critically affects bone marrow function. Our published studies demonstrate that diabetes-induced 
derailment of cholesterol and sphingolipid metabolism leads to shift in LTR/STR-HSCs, as well as 
myeloid/lymphoid cell balance. As we previously demonstrated, the central enzyme of sphingolipid 
metabolism, acid sphingomyelinase (ASM) is highly upregulated in bone marrow niche in diabetes. 
As shown in Figure 2, when injected into the vitreous, control HSC migrate into the areas of retinal 
vascular damage, home to the vasculature and aid in the repair process. Diabetic HSCs with a high 
level of ASM expression level lose the ability to migrate and thus remain in the vitreous and do not 
participate in vascular repair.  Inhibition of ASM in HSCs greatly improved HSC migration, homing to 
retinal vasculature and repair potential. Interestingly, when injected into the control eyes, normal 
Figure 2: Inhibition of acid sphingomyelinase in diabetic CACs corrects their dysfunction. Diabetic 
animals received intravitreal injections of control (A), diabetic (B), or diabetic CACs treated with siRNA for 
ASM (C). CACs (green) were isolated from gfp+ mice, retinal vasculature was stained with anti-collagen IV 
antibody (red), and localization (yellow) indicates vascular association. Diabetic CACs show reduced 
localization with vasculature (middle), while ASM inhibition improved vascular association of diabetic CACs 
(right). Abbreviations: ASM, acid sphingomyelinase; BM, bone marrow; CAC, circulating angiogenic cell. 
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control HSCs migrate out of the vitreous and return to the bone marrow niche [22]. Diabetic HSCs 
with high ASM do not migrate and remain in the vitreous. Inhibition of ASM in diabetic HSC restores 
their migration ability. 
3. WHY IS BONE MARROW PATHOLOGY LINKED TO THE PATHOGENESIS OF DIABETIC 
RETINOPATHY? 
For the last decade, it has become increasingly evident that bone marrow dysfunction plays a 
key role in the pathogenesis of DR. Diabetes accelerates bone marrow HSCs aging which not only 
promotes myeloid-biased HSCs but also induces a rapid decline in LTR-HSCs from the bone marrow 
(8). Diabetes impairs the bone marrow architecture, function, and numbers of reparative cells. 
Diabetes also impacts bone marrow - derived immune cells. Typical features of diabetic bone marrow 
include microangiopathy, neuropathy, stem cell rarefaction, and extensive fat deposition, along with 
increased apoptosis leading to reduced numbers of reparative cells such as CD34+ cells [23-26]. 
Neuropathy results in reparative cells being trapped in the bone marrow unable to enter the circulation 
for homing to regions, such as the retina in need of repair [27-29]. There is a normal circadian 
regulation of release of reparative cells in healthy subjects. This release of reparative cells occurs 
during the rest phase. The traffic of both reparative cells and immature immune cells from the bone 
marrow occurs in response to activation of β-adrenergic receptors expressed on hematopoietic stem 
cells, osteoblasts, and mesenchymal stem cells. Previously, we showed that there are changes in the 
level of innervation of the bone marrow in diabetes. We showed that very early in the natural history 
of diabetes, the peripheral nerves innervating the bone marrow respond to the abnormal diabetic 
milieu and oxidative injury by compensatory neurogenesis  [27];  whereas later on there is a dramatic 
reduction in the number of sympathetic nerves within the bone marrow by immunohistochemistry 
(IHC) [30].  
3.1 DIABETIC MOBILOPATHY 
Loss of innervation results in a ‘mobilopathy‘ in which bone marrow cells are trapped in the 
bone marrow and are not released into the systemic circulation. This mobilopathy occurs in both 
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diabetic rodents and humans. Possible mechanism responsible for the development of this 
mobilopathy include: (i) an aberrant response to beta-adrenergic stimulation, (ii) failure of nestin-
positive mesenchymal stem cells to downregulate the CXCL12 expression [31, 32], (iii) defective 
hypoxia-inducible growth factor signaling [33], (iv) tissue-specific alteration in dipeptidyl peptidase-4 
(DPP-4) [34], (v) decrease in the levels of cytokines such as SDF-1 and osetoprotegerin, (vi) increase 
in oxidative stress, DNA damage and apoptosis [26] and (vii) diabetes-induced increase in cell and 
plasma membrane rigidity [22, 35]. 
Clinical evidence of the mobilopathy is provided by retrospective analysis of bone marrow 
transplant subjects. These studies suggest that individuals with T1D and T2D have reduced 
mobilization of CD34+ cells in response to stimulation by granulocyte colony-stimulating factor (GM-
CSF) [36]. We interpret this finding as presence of bone marrow neuropathyin these individuals and 
showed in a type 2 model that denervation is associated with reduced blood flow in the bone marrow 
(Figure 3).    
Long-standing diabetes results in an imbalance of bone marrow lymphocyte and monocyte 
populations and a selective decline of HSCs. The increase in bone marrow-myelodiosis is reflected 
in an increase in the monocytic population in peripheral blood which is seen not only in rodent models 
[37, 38]  but also in humans [28]. While diabetes promotes the production of myeloid-biased HSCs, 
Figure 3: BBZ/Wor T2D rats exhibit reduced blood flow to the bone marrow. A significant reduction 
in blood flux is observed in T2D rats compared to controls in both the BM and sciatic nerve. (A) 
Background showing exposed femur under retraction. Target area was imaged using a laser Doppler 
(LDPI) for relative blood flux and color charted (arrow and inset). Examples of LDPI of bone marrow (B & 
C) and sciatic nerve (D & E) in a control and T2D rat respectively. Warm (red) colors represent regions of 
relative high flux whereas cool colors (blue) represent areas of low flux. F: Quantification of LDPI imaging 
is shown in control (n = 4) and diabetic (n = 4) rats.  
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it also induces a rapid decline in LTR-HSCs from the bone marrow endosteal niche with an increase 
in more committed STR-HSCs near the sinusoidal niche [39].  
Since the diabetic microvasculature is in constant demand for new cells to ‘replace’ dying 
endothelium and to keep the vasculature healthy following an ischemic insult [10], an increase in 
STR-HSCs provides a ready source of vascular supporting cells; however, these cells can become 
exhausted.  Not only are the numbers of these cells reduced, but also the cells exhibit dysfunctional 
behavior with reduced migratory function.   
3.2 PHENOTYPIC CHARACTERIZATION OF BONE MARROW CELLS 
Previously, we showed that healthy peripheral blood derived (non-diabetic) CD34+cells (human 
vascular progenitors) home to areas of injury in the diabetic retina and in the ischemia/reperfusion 
(I/R) retinal injury model [40]. CD34+ cells represent a population of progenitor cells that: i) are 
hematopoietic in origin and express CD45+, CD14+, CD145lo, VE-CAD+/-, CD105+, vWF+/-, CD133+, 
CXCR4+, VEGFR1+, and VEGFR2+ among other surface receptors; ii) consistently contribute to 
revascularization by providing paracrine support to the resident vasculature; iii) are easily isolated 
from peripheral blood, bone marrow and umbilical cord blood and iv) are currently in clinical trial for 
advanced DR (ClinicalTrials.gov Identifier: NCT01736059) [41]. However, the initial results have 
shown only modest improvement in visual outcomes [41], likely due to the defective function of the 
autologous diabetic CD34+ cells being injected.  
A weakness of this research is that multiple mechanisms have been identified for this 
dysfunction, thus targeting a single pathway results only in the partial and transient improvement 
of CD34+cell function. A further weakness in most studies, including our own, is the use of only a 
single marker to isolate/identify these cells. The reason being is that the number of human cells 
available to study is reduced by each marker used for selection and the starting number of these 
cells (isolated from peripheral blood of diabetic individuals) is often severely limited. The “single 
marker isolation” results in a very heterogeneous population of cells for studies. Furthermore, 
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there is disagreement about what additional markers should be used for characterization, for 
example, VEGFR2 or CD133 or CXCR4, making it difficult to compare results between different 
human studies that have used multiple markers [42-44]. In essence, CD34+cells represent an 
incompletely characterized population [45]. A further weakness is that murine stem/progenitors 
are characterized by different surface markers than humans, making it difficult to compare 
between species [46]. 
4. THE BONE MARROW- BRAIN CONNECTION IN THE PATHOGENESIS OF DIABETIC 
RETINOPATHY 
5. An imbalance in the sympathetic nervous system, with the loss of parasympathetic drive and 
increased sympathetic activation, occurs in diabetes. Ultimately these neuronal changes 
transition to neuronal loss and in the bone marrow can directly impact diabetic retinopathy [16, 
17, 27, 28, 30, 37, 38, 47-50]. In chronic diabetes bone marrow denervation occurs and 
precedes the onset of diabetic retinopathy in rodent models of diabetes [28, 30, 37, 49]. The 
altered neuronal input to bone marrow stromal cells (due to diabetes-induced peripheral 
neuropathy) results in the altered production of growth factors/cytokines. Hematopoiesis shifts 
away from the generation of reparative vascular progenitor cells towards the production of 
excessive numbers of deleterious pro-inflammatory (CCR2+) monocytes that enter the systemic 
Figure 4: Increased density of Iba-1+ microglia and a decreased density of NeuN+ 
neurons in the hypothalamus of type 2 diabetic (T2D) rats. Brain sections of hypothalamic 
region of control (A), T2D (B) rats showing Iba-1 staining in red and NeuN in green. (C) Bar 
chart showing relative quantitation.  Scale bar = 100 µm. 
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circulation. Importantly, monocytosis is not limited to rodent models but is also observed in T1D 
human subjects. Sympathetic hyperactivation results in hypoxia of these autonomic centers 
which results in CCL2 expression [51]. Bone marrow -derived CCR2+ cells home to these 
regions (responding to the local CCL2 gradient) where they become activated. Activated bone 
marrow-derived macrophages in these regions stimulate resident microglia (Figure 4). CCR2+ 
monocytes also home to the retina to promote diabetic retinopathy pathology [28, 48]. As 
discussed above, diabetic dyslipidemia with increased activity of ASM in diabetic bone marrow 
affects the balance between 
pro-inflammatory 
macrophages and reparative 
progenitor cells.  Use of 
chimeric mice with 
fluorescently labeled bone 
marrow cells allows bone 
marrow-derived cells to be 
easily detected in peripheral 
tissues. Inhibition of ASM only 
in the bone marrow niche 
using ASM-/- BMT was 
sufficient to prevent retinal 
microglia activation, as well as 
to inhibit diabetes-induced 
inflammation and retinal 
vascular damage (Figure 5).  
Figure 5: BM-ASM inhibition prevents activation of 
microglia in diabetic retinas. Confocal images of retinal 
flat mounts from bone marrow chimeras with GFP (green), 
or GFP-ASM-/- bone marrow donors and wild type recipient 
mice.  The retinas are stained with collagen IV for the retinal 
vasculature (red). (A) Control retina showing resting 
microglia with the typical ramified and branching shape. (B) 
Diabetic animals show activated microglia with more 
compact cells with fewer ramifications. (C) Diabetic animal 
showing that BM-ASM inhibition prevents activation of 
microglia. (D) Bar chart showing the quantification of the 
percentage of activated microglia in the three conditions. 
Scale bar is 50 µM, n=8 
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There is sympathetic drive/norepinephrine (NE) spillover and a decrease in parasympathetic 
drive [52-54] to the peripheral organs [55, 56], resulting in end-organ damage (15); 
vascular/endothelial dysfunction [57], and hormonal imbalance (17) in diabetes.  Thus it can be 
reasoned that changes in autonomic nervous system (ANS) activation can have a role in the 
pathogenesis of diabetic complications including diabetic retinopathy [28, 48]. Previously, others 
and we have shown that early on in the natural history of diabetes there is an increase in 
neurotransmission in key regions of the hypothalamus. The excitatory neurotransmitter, 
glutamate is increased in diabetes [58]. Increased orexin (ORX) immunoreactivity occurs in 
diabetes and localizes to neurons of the lateral and posterior hypothalamus, primary sites of the 
brain wherein ORX acts to stimulate food intake and energy homeostasis. Activation of ORX 
neurons in the hypothalamus increases sympathoadrenal pathways to release epinephrine [59, 
60]. Intracerebroventricular injections of ORX increased arterial pressure, renal sympathetic 
neuronal activity, and levels of vasopressin, epinephrine, and plasma glucose. Hypothalamic ORX 
immunoreactive projections to the rostral medulla can stimulate the cardiovascular center [61] 
and activate preganglionic sympathetic neurons in spinal cord. Both oxytocin and vasopressin are 
excitatory neurotransmitters found in descending projections to sympathetic premotor neurons 
[59]; levels of both are increased in diabetes (21). Oxytocin and vasopressin localize with the 
catecholamine synthesis marker tyrosine hydroxylase in PVN neurons [62-64], and the 
expression of these excitatory neurotransmitters and neuropeptides has been shown to be 
increased in diabetes [65, 66]. 
Not only are excitatory neurotransmitters increased, but there are reductions in inhibitory 
neurotransmitters such as a gamma amino butyric acid (GABA) and somatostatin (SST) [67], 
further serving to promote an increase in ANS activation. SST is released from a subclass of 
GABAergic inhibitory neurons that can be part of a local circuit or be projecting [68, 69].  Studies 
have shown that a deficiency or hypofunction of GABAergic mechanisms in the hypothalamus 
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may be related to the pathogenesis of a variety of clinical conditions characterized by altered 
sympathetic nerve activity, such as hypertension [68, 70], and heart failure [71] and diabetes. 
Hambley et al. [72], reported significant reductions in endogenous hypothalamic GABA (inhibitory) 
concentrations and in the density of GABAA receptors in spontaneously hypertensive/metabolic 
syndrome rats compared to control [71-73]. Complementary glutamatergic mechanisms are 
involved in NMDA-mediated sympathetic outflow in the hypothalamus in heart failure due to 
NMDA receptor upregulation [74].  
Autonomic centers innervate the bone marrow and tracing studies show direct 
connections between the brain SST neurons and the bone marrow. The bone marrow neuropathy 
is accompanied by altered blood flow to the bone marrow that contributes to the ongoing 
pathology. Using the BBZ/Wor rat model of type 2 diabetes, we show that somatostatin levels fall 
in the hypothalamus compared to controls. We also observe that these autonomic nuclei 
simultaneously exhibit increased regional inflammation. Based on published work, the source of 
this inflammation includes extravasation of circulating cells [75].  
Thus, early in diabetes, there is an over-activation of the ANS whereas later there is 
denervation. IHC studies of BBZDR/Wor transgenic rats with T2D demonstrate loss of 
somatostatin-immunoreactive neurons in the hypothalamus (Figure 6), and co-localization of 
somatostatin with neurons labeled following bone marrow injections of Pseudorabies virus (Figure 
Figure 6: Decrease in SST+cells in the hypothalamus in type 2 diabetic rats. Brain sections 
from age-matched nondiabetic lean BBZ rats (A) show robust cellular SST staining compared to 
that observed in diabetic BBZ/Wor rats with 4 months of diabetes (B). 3V = third ventricle. Scale 
bar = 50µm. (C) Quantitation shows a statistically significant decrease in the number of SST+ 
cells with diabetes (n=4, *P<0.05). 
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7). These data indicate a marked adverse effect of diabetes on 
hypothalamic somatostatin expression and show that 
somatostatin-expressing neurons project to the bone marrow 
whereby aberrant signaling and ultimately their loss could 
produce bone marrow pathology and contribute to development 
of DR. While somatostatin neurons represent one population of 
neurons that are lost early in the natural history of diabetes, 
previously we showed tyrosine hydroxylase expressing 
neurons are also reduced and that loss of adrenergic nerves 
influences hematopoiesis and vascular repair mechanisms [30, 
37, 38, 49, 76, 77] 
  There are several possible mechanisms responsible for 
sympathoexcitation seen in early diabetes [78]. Poor passage 
of leukocytes through the microcirculation in diabetes leads to increases in vascular resistance, 
with reduced blood perfusion and oxygen delivery producing sympathoexcitation by inadequate 
brain perfusion at the level of the microvasculature. The idea that inadequate brainstem perfusion 
leads to excessive sympathetic nerve activity is not new and was postulated by Cushing in the 
early 1900s. Moreover, within the rostral ventrolateral medulla (RVLM), a region generating 
activity destined for the sympathetic preganglionic motor neurons, there are neurons which are 
intrinsically sensitive to hypoxia [79]. The latter provides a transduction mechanism by which the 
low perfusion of the brainstem results in sympathoexcitation to ensure adequate perfusion (33). 
Thus, the brain is well prepared to ‘self-protect’ at multiple levels of the neural axis in response to 
the potential threat of low oxygen.  
Figure 7: Somatostatin+ 
nerves project from the 
hypothalamus to the bone 
marrow. Confocal (60X) z-
projection of hypothalamic 
periventricular region from a rat 
that received femoral bone 
marrow injection of PRV-152 
(green) also immune-labeled for 
SST (red). 3V = third ventricle. 
Scale bar = 24µm.  
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Central sympathetic activity has a direct impact on inflammatory cytokines. For example, 
sympathetic tone is positively correlated with interleukin 6 (IL-6) plasma levels (24). Central 
inhibition of the ANS decreases 
TNF serum levels (24, 25). 
Similarly, stress responses that 
modulate ANS activity impact the 
inflammation (26). We have shown 
previously that peripheral immune 
challenges produce activation of 
sympathetic associated brain 
nuclei (27). In turn, neuro-
inflammation in these ANS regions 
can cause an auto-perpetuating 
cycle of excitation of autonomic 
neurons to sustain bone marrow 
pathology [28] (Figure 8).  
VASCULAR WALL DERIVED 
PROGENITOR CELLS 
Endothelial cell colony 
forming cells (ECFCs) represent a 
second [16, 40, 80, 81] population 
of cells possessing vascular 
reparative activity [82, 83]. ECFCs, 
also called “outgrowth endothelial 
cells” [83] have the high 
proliferative capacity and the ability to maintain an endothelial phenotype throughout ex vivo long-
Figure 8: The bone marrow is a critical target organ of 
diabetes and its dysfunction can adversely affect diabetic 
retinopathy. The release of bone marrow cells and 
hematopoiesis is under the regulation of the 
autonomic nervous system (ANS) and in late stage diabetes 
denervation of the bone marrow results in a shift in 
hematopoiesis with loss of generation of reparative cells but 
an increased production of pro-inflammatory cells. Therapeutic 
targets and novel strategies may include modulation of bone 
marrow ATM, ASM, and FOXO, systemic administration of 
Ang 1-7 or exogenous replacement of SST using a 
somatostatin analogue that crosses the BBB to influence the 
brain.  Preservation of bone marrow function may represent a 
new opportunity for treatment and management of diabetic 
retinopathy. 
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term expansion [84]. These cells are CD34+but CD45- and can be further distinguished by being 
CD14-, CD115-, CD146hi, VE-CAD+/+, CD105+ vWF+, CD133-.  We and others have shown that 
ECFCs are capable of i) integrating into pre-existing retinal vessels, ii) de novo retinal capillary 
formation in several in vitro models and iii) de novo capillary formation in in vivo retinal models 
[85-87]. Furthermore, ECFCs injected into the systemic circulation of SCID mice are able to 
correct ischemia and lodge and survive in nine different vascular beds for up to 7 months after 
intravenous tail vein injection, without inducing thrombosis or infarcts [88]. Following acute 
vascular injury, the ability of ECFCs to repair and regenerate can be augmented by the addition 
of healthy CD34+CD45+ cells [89]. 
Previously, we examined CD34+cells and ECFCs circulating in the blood of individuals with 
microvascular complications (MVC) [90]. Circulating mononuclear cells from diabetic and 
nondiabetic individuals were used to isolate CD34+cells and grow ECFCs in culture. ECFCs could 
only be obtained from 15% of diabetic individuals tested, and these represented individuals 
without DR or other microvascular complications, whereas ECFCs could be obtained from 100% 
of the control individuals. This severely restricted ECFC studies to individuals without MVC and 
this represented a limitation of using these cells for autologous cell therapy.  Similarly, depletion 
of ECFCs from the blood and blood vessels of individuals with the peripheral vascular disease 
has been reported [91]. 
 Similarly, CD34+ cells from diabetic individuals with MVC are dysfunctional [92-103]. Since 
the major function of CD34+ cells is to provide paracrine production of growth/trophic factors, we 
examined conditioned medium (CM) derived from CD34+ cells of diabetic individuals (diabetic-
CM). The levels of key stem cell survival factors (stem cell factor, hepatocyte growth factor, and 
thrombopoietin) were found to be markedly lower, while the expression of pro-inflammatory 
factors, such as IL-1β and tumor necrosis factor (TNF-α) levels were markedly higher in diabetic-
CM than in CM-derived from nondiabetic individuals (nondiabetic-CM). Hypoxia did not upregulate 
18 
 
HIF-1α in CD34+ cells of diabetic origin but did in CD34+cells isolated from healthy controls. Both 
migration and proliferation of nondiabetic (healthy) CD34+ cells toward diabetic-CM were lower 
compared to nondiabetic-CM. We also demonstrated attenuation of pressure-induced 
constriction, potentiation of bradykinin relaxation, and generation of cGMP and cAMP in arterioles 
were observed with nondiabetic-CM, but not with diabetic-CM. In contrast, diabetic-CM failed to 
induce endothelial tube formation from vascular tissue. Thus, the major findings of this study [90], 
are that the use of either CD34+ cells or ECFCs as a cell therapy is severely limited because 
CD34+ cells are dysfunctional (impaired autocrine/paracrine function and reduced sensitivity to 
hypoxia) and the vascular wall ECFCs are depleted and essentially unobtainable from individuals 
in need of cell therapy [90, 104-106]. Advanced age also limits the function of CD34+ cells and 
isolation and expansion of ECFCs [107]. Thus, our published studies and those of others 
emphasize i) the limitation of using autologous peripheral blood derived cells from diabetic 
individuals with MVC, ii) the need for alternative autologous cells for improved cell therapy, for 
example iPSC derived cells, iii) prevention of the loss of this critical vascular wall reparative 
population, the ECFCs and/or iv) the need to correct diabetes –induce bone marrow dysfunction.  
 
BONE MARROW CELLS FOR THERAPY 
 Several studies over past years suggest that cell-based therapies hold a countless promise 
for revascularizing endothelial loss during diabetes. Park et. al. has eloquently and comprehensively 
described the current literature regarding cell therapy for retinal diseases [108]. Thus, this section 
will only highlight as few aspects of cell therapy for DR. There are a variety of sources for cell 
therapy such as circulating angiogenic cells, endothelial colony forming cells, mesenchymal stromal 
cells (MSCs), embryonic stem cells, and inducible pluripotent stem cells (iPSCs).  
 Our research over past several years suggests that diabetes leads to a dysfunction of the 
CD34+ cell.  The CD34+ cells obtained from diabetic individuals exhibit a decrease in migration, 
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proliferation, and incorporation in blood vessels. Our studies indicate that nitric oxide is a critical 
determinant of CD34+ plasticity. We successfully used a variety of pharmacological agents such as 
transforming growth factor (TGF-β1) morpholino [109], angiotensin 1-7 (Ang 1-7) [80] to correct 
low levels of NO and restore the functional ability of diabetic CD34+ cells. 
 The MSCs play an important role in the treatment of microvascular complications due to their 
multipotency and paracrine mechanisms. Allogeneic mesenchymal stem cells secrete neurotrophic 
factors, growth factors, adipokine, polarizing M2 macrophages, and inhibiting inflammation [23, 24, 
110].   MSCs derived from adipocytes (i.e. adipose derived stem cells) resemble retinal pericytes. 
ASC help in the treatment of injured retina either by paracrine repair [111]. 
Some studies attempted to generate iPSCs cells from cord blood CD34+ cells. The iPSCs 
cells were generated using a treatment with VEGF [112]. The injection of these iPSCs cells into the 
vitreous of NOD/SCID mice lead to an improvement of ischemic injury. Injected iPSC cells also 
aligned near the luminal side of blood vessels, indicating their potential as a vessel-building cell 
[113].  
PHARMACOLOGICAL APPROACHES  
The bone marrow as a whole is relatively hypoxic with a pO2 of 32 mm of Hg.  The oxygen level 
in different parts of the bone marrow varies considerably. The areas near the sinusoids are more 
hypoxic due to poorer perfusion (pO2, 9.5 mm Hg), while the areas nearer to the endosteum are more 
perfused (pO2, 13.5 mm Hg) [114].  Typically, the relative hypoxia in the bone marrow helps to 
maintain the long-term repopulation of HSCs, however, the oxidative stress from diabetes and aging 
induces DNA damage, compromising the repopulating ability of HSCs. Considering the hypoxic 
nature and the reduced level of perfusion of the bone marrow, it is a challenging region for drug 
delivery [115].  
Lowering blood glucose exhibits some level of protection in bone marrow niche function and 
helps with the mobilization of HSCs [33].  The DPP-4 inhibitor, a commonly prescribed 
20 
 
pharmacological agent for lowering blood glucose in diabetic individuals affects bone marrow function 
by regulating the SDF-1. DPP-4 inhibition in clinical studies lead to mobilization of stem cells and 
promoted vascular recovery in an animal model of ischemia [34].  
As mentioned earlier, LTR-HSCs preferentially reside in endosteal regions of the bone marrow 
within vicinity to osteoblasts [116]. Studies performed using hematopoietic chimeras suggest a 
significant contribution of hemangioblast of bone marrow origin in the repair of and maintenance of 
retinal vasculature. About 10% of endothelial cells in neovessels that developed in response to an 
injury are bone marrow-derived [117]. However, under the chronic metabolic stress of diabetes, there 
is a decline of LTR-HSCs from the well conserved osteoblastic niche leaving primarily the local 
endothelium to undertake the repair of damaged vasculature endangering retina to site threatening 
proliferative DR  [26]. Drug targeting to osteoblast cells is of intense interest in order to control HSC 
quiescence or egress. LTR-HSC’s rapid mobilization can be induced by targeting α9β1/α4β1 integrins 
through a single dose of the small molecule BOP (N-(benzene sulfonyl)-l-prolyl-l-O-(1-
pyrrolidinylcarbonyl) tyrosine) [118]. Transgenic mice with increased osteoblast in bone marrow show 
an increase in HSCs near the endosteal niche.  The granulocyte colony stimulating (G-CSF) causes 
HSC egress via transient ablation of osteoblast cells from bone marrow [119]. Moreover targeted 
deletion of Dicer-1 (necessary for the maturation and processing of all microRNAs) in 
osteoprogenitors results in an altered hematopoiesis with the distorted generation of selected 
lineages [120]. These studies support the assertion that endosteal region and osteoblast provide a 
unique environment necessary for HSC self-renewal, quiescence, and survival, providing an ideal 
target for therapeutic delivery. One of the striking findings of studies involving osteoblast depletion is 
the concurrent loss of bone marrow macrophages, suggesting a vital role of bone marrow 
macrophages in maintaining endosteal HSC niche. Liposome-mediated drug delivery to 
macrophages efficiently targets bone marrow, however, once liposomes are ingested by the 
macrophages, the phospholipid bilayers of the liposomes are disrupted under the influence of 
lysosomal phospholipases leading liposomal  ‘suicide’ causing a non-specific delivery of drug 
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molecules [121]. Some studies have also targeted E-selectin which is constitutively expressed on 
bone marrow endothelium using E-selectin thioaptamer conjugated to porous silicon particle [122].   
Bone-targeting molecules such as bisphosphonates and oligopeptides can aid in the delivery 
of drug molecules to the bone marrow.  Recent studies indicate that oligopeptide (AspSerSer)6 binds 
efficiently to slowly crystallized area in osteoblast cells and amorphous calcium phosphates. In fact, 
a recent study using (AspSerSer)6 oligopeptide linked to 1,2 Dioleoyl-3-Trimethylammonium-Propane 
(DOTAP)-based cationic liposome encapsulated with osteogenic siRNA markedly promoted bone 
formation and bone mass [123]. Boosting antioxidant pentose pathway with treatment with 
benfotiamine has shown to be protective in restoring the depletion of stem cells. In addition, control 
of dyslipidemia-induced damage by normalizing BM cholesterol metabolism through activation of 
LXR, or normalizing sphingolipid metabolism through inhibition of ASM in diabetes could provide an 
effective way of restoring the balance between BM-derived pro-inflammatory and reparative cells, as 
well as improving progenitor cell function. As mentioned earlier, ASM inhibition reduced diabetes-
induced retinal vascular damage. Several tricyclic antidepressants (TCA), including amitriptyline, 
clomipramine, and desipramine, have shown promise at inhibiting ASM [124, 125]. The single cell 
model explanation for this occurrence is that TCAs accumulate in the lysosome and interfere with 
ASM binding, resulting in it being inactivated via proteolytic degradation [125]. Norepinephrine 
reuptake inhibitors might also present a viable strategy to combat BM dysfunction due to the high 
probability that neuropathy will also affect the diabetic BM [44]. 
 
CONCLUSION  
The bone marrow is a critical target organ of diabetes and its dysfunction adversely affects the 
outcome of diabetic microvascular complications. Diabetes leads to selective depletion of most 
primitive HSCs from the bone marrow. This not only compromises the source of a reparative stem cell 
but also creates a state of oxidative stress due to enhanced production of short-term repopulating 
HSCs. Strategies used in promoting bone marrow niche function holds a significant potential for bone 
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marrow rejuvenation, however, targeted delivery of pharmacological agents to bone marrow is a 
challenge due to relative hypoxia of the bone marrow and difficulty of delivering drugs to the bone 
marrow. Osteoblast-targeted drug delivery is a viable option for delivering drug molecules to endosteal 
niche and experimental studies are promising, in future, these therapies would be available for patient 
use. 
The release of bone marrow cells and hematopoiesis is under the regulation of the ANS, which 
responds early on in diabetes with hyperactivation in an attempt to respond to diabetes-induced 
changes in perfusion of key autonomic centers. Later in the natural history of diabetes, denervation of 
the bone marrow occurs and results in loss of a generation of key reparative cells while fostering the 
generation of increased numbers of pro-inflammatory cells. Therapeutic targets and novel strategies 
directed at the preservation of bone marrow function may represent a new solution to treatment and 
management of diabetic retinopathy. 
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